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Abstract
To determine incidence and type of major cardiac adverse events in patients with mutated desmin (DES) gene, we retrospectively
reviewed baseline medical information, and examined the long-term outcomes of 28 DES patients (17 men, baseline mean
age = 37.7 ± 14.4 years [min = 9, max = 71]) from 19 families. Baseline studies revealed skeletal muscle involvement in 21 patients
and cardiac abnormalities in all but one patient. Over a mean follow-up of 10.4 ± 9.4 years [min = 1, max = 35], cardiac death occurred
in three patients, death due to cardiac comorbidities in two, one or more major cardiac adverse events in 13 patients. Among the 19
patients with mild conduction defects at baseline, eight developed high-degree conduction blocks requiring permanent pacing. Cardiac
involvement was neither correlated with the type of DES mutation nor with the severity of skeletal muscle involvement. Our study
underscores that in DES patients in-depth cardiac investigations are needed to prevent cardiac conduction system disease.
 2011 Elsevier B.V. All rights reserved.
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1. Introduction
Desmin is a cytoskeletal protein which forms intermedi-
ate ﬁlaments and interacts with other proteins to create an
intracytoplasmic network. This protein is known to play an
important role in the attachment, stabilization, and force
transmission of the sarcomeres in skeletal and cardiac mus-
cle cells [1]. Desminopathies encompass the genetic diseases
caused by mutations in the human desmin gene (DES) on
chromosome 2q35 [2,3]. In those rare diseases, clinical
manifestations include familial or sporadic cardiomyopa-
thies [4–7], and skeletal muscle weakness with myoﬁbrillar
changes, or both of them [8–15].
Dilated, hypertrophic or restrictive cardiomyopathies,
and arrhythmias have all been reported in patients with
desminopathy [8–13], however the prognostic signiﬁcance
of these abnormalities is not well known due to absence
of long-term outcome studies. Therefore, no consensus
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has been reached regarding the best diagnostic and thera-
peutic strategies in patients with desminopathy.
The objectives of this longitudinal retrospective study
were to (a) analyze clinical information based on standard-
ized skeletal muscle and cardiac investigations in consecu-
tive patients suﬀering from DES mutations, and (b)
examine their long-term clinical outcomes with particular
focus on the incidence and type of major cardiac adverse
events (AEs) during follow-up.
2. Patients and methods
We retrospectively identiﬁed the consecutive patients
with DES mutations who, between 1981 and 2009, were
referred to the neurology, cardiology or genetics units of
the Pitie´ Salpeˆtrie`re, Cochin and Lausanne University Hos-
pitals, for evaluation and treatment of skeletal muscle or
cardiac disease manifestations, or for systematic family
screening. The standardized muscle and cardiac studies
they underwent at diagnosis were repeated atleast every
2 years. The baseline cardiac and muscle assessments, as
well as cardiac complications which occurred during fol-
low-up (see cardiac studies, below), were retrospectively
entered in a dedicated database.
2.1. Standard protocol approvals, registrations, and patient
consents
The study was approved by the ethics committee of the
participating institutions, and the patients granted their
informed consent to contribute their medical information
to this analysis.
2.2. Genetic testing
Blood samples were collected after obtaining written
informed consent from all patients. Genomic DNA was
extracted from peripheral blood lymphocytes using the
Genomic–Mega-Extractor (EXTRAGENE) and PRO-
MEGA chemistry according to the manufacturer’s
procedures.
A series of primer pairs (available on request) was
designed to amplify the 9 coding exons and ﬂanking intro-
nic sequences of DES based on the published sequence
(GenBank accession number NG_008043.1). After puriﬁca-
tion, the PCR products were sequenced on both strands
using the ABI BigDye Terminator v3.2 Kit (Applied Bio-
systems, Foster, CA) and run on an ABI3730 device
(Applied Biosystems). SeqScape Software was used to
facilitate data analysis and mutation identiﬁcation followed
by visual inspection of individual sequencing traces.
Detected variants in a sample were conﬁrmed by an inde-
pendent PCRs and sequencing runs. An analysis with Ala-
mut Software (Interactive Biosoftware, Rouen, France) was
systematically conducted to predict possible impact on any
amino acid substitution. Genetic variants were annotated
according to the protein and cDNA reference sequences
(UniProtKB/Swiss-Prot P17661 and NM_001927.3). Sev-
eral criteria were used to determine if a new variant is a rare
polymorphism or a potential disease causing mutation; (i)
the conservation of the nucleotide and the aminoacid
among species and isoforms, (ii) the absence of the variant
in control chromosomes, (iii) the modiﬁcation of charge of
the mutated residue, (iv) the cosegregation in aﬀected indi-
viduals of the same family.
2.3. Muscle investigations
At the time of diagnosis, all probands underwent (a) a
detailed physical examination by a neurologist specialized
in muscle disorders, (b) measurement of serum creatine
kinase level (CK), and (c) a muscle biopsy. All probands’
relatives were investigated according to the same protocol,
but muscle biopsy was not systematically performed.
2.4. Cardiac studies
The cardiac studies included electrocardiograms (ECG)
and echocardiograms [14] recorded at baseline and during
follow-up in all patients. Patients whose ECG revealed
the presence of conduction abnormalities underwent 24-h
ambulatory ECG. Coronary angiography was performed
in patientsP 40 years of age and evidence of left ventricu-
lar dysfunction, to exclude the presence of ischemic
cardiomyopathy.
Cardiac involvement was considered present in patients
with (a) abnormalities of impulse propagation, deﬁned by a
PR interval > 200 min or a QRS duration > 110 min, (b)
sustained atrial arrhythmias, (c) non-sustained or sustained
ventricular tachycardia, or (d) left (LV) or right ventricular
(RV) dilation, hypertrophy or systolic dysfunction. Car-
diac adverse events (AEs) were classiﬁed as major when
the following conditions were encountered; (a) sustained
ventricular tachyarrhythmias, (b) > 3 s asystole or 3rd
degree atrio-ventricular (AV) block, (c) supraventricular
arrhythmias with cardioembolic stroke, (d) worsening of
heart failure needing treatment as an inpatient or needed
cardiac transplantation, and (e) death from a cardiovascu-
lar cause.
2.5. Statistical analysis
The data are expressed as means ± standard deviation
(SD) for continuous variables and numbers and percent-
ages for categorical variables. The possible role played by
selected variables, including muscle weakness and gene
mutations, in relationship with the presence of any cardiac
event was examined by single variable analysis. Student’s
t-test was used for comparisons of normally distributed
continuous variables, and chi-square or Fisher’s exact test
for diﬀerences in frequency, as appropriate. The incidence
of all and of major cardiac AEs was analyzed, using the
Kaplan–Meier method. All analyses were performed with
212 K. Wahbi et al. / Neuromuscular Disorders 22 (2012) 211–218
Author's personal copy
the STATA statistical software, version 10.1 (StataCorp
LP, College Station, TX).
3. Results
3.1. Patient population
We identiﬁed 28 patients (17 men, mean age 37.7 ±
14.4 years), from 19 families, with DES mutations. Pro-
bands were patients who were referred to Neurology Units
for the assessment of muscle symptoms. The genetic screen-
ing of probands’ relatives displayed a DES mutation in 9
individuals, including 7 who had no prior history of muscle
or cardiac disease, 1 with a previously undiagnosed myop-
athy, and 1 with a history of severe arrhythmia. A familial
transmission of the disease with an autosomal dominant
pattern was found in 16 independent index patients (with
a total of 25 patients or mutation carriers). Familial genetic
screening could not be performed to diﬀerentiate de novo
mutations from autosomal dominant transmissions in 3
patients who presented with sporadic cardiac and muscle
disease.
3.2. Genetic analyses (Table 1, Fig. 1)
Sequencing DES gene led to the identiﬁcation of 18 dif-
ferent mutations in the 19 unrelated patients. Eleven muta-
tions had already been described, while 7 are novel ones.
The novel mutations consisted in 4 null mutations; a stop
codon p.Lys144X, two splice sites mutations aﬀecting
exon 3;c.640–2:A>C, c.735 + 3:A>G and a mutation trans-
forming the termination codon in a coding codon
p.X471Tyr and thus giving rise to a putative longer pro-
tein. Four mutations resulted in substitution codons,
Table 1
DES mutations for each family studied.
Family Mutation cDNA (NM_001927.3) Mutation localisation Mutation type
1 p.Leu338Arg c.1013T>G 2B helix Missense
2 p.Pro419Ser* c.1255C>T Tail Missense
3 Putative exon 3 skipping* c.640–2A>C 1B helix Splice
4 p.Asp336Tyr* c.1006G>T 2B helix Missense
5 p.X471Tyr* c.1413A>C Tail Abolition Ter codon
6 p.Lys144X* c.430A>T 1B helix Non sense
7 p.Arg454Trp c.1360C>T Tail Missense
8 p.Glu245Asp or exon 3 skipping* c.735G>T 1B helix Missense or splice
9 p.Arg406Trp c.1216C>T 2B helix Missense
10 p.Glu439Lys* c.1315G>A Tail Missense
11 p.Ser2Ile c.5G>T Head Missense
12 p.Ser2Ile c.5G>T Head Missense
13 p.Thr442Ile c.1325C>T Tail Missense
14 p.Asn342Asp c.1024A>G 2B helix Missense
15 Putative exon 3 skipping c.735 + 3A>G 1B helix Splice
16 p.Arg355Pro c.1064G>C 2B helix Missense
17 p.Arg454Trp c.1360C>T Tail Missense
18 p.Glu413Arg c.1237_1238delinsAG 2B helix Missense
19 p.Leu345Pro c.1034T>C 2B helix Missense
* New mutations.
Fig. 1. Desmin mutations.
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p.Asp336Tyr, p.Pro419Ser, p.Glu439Lys. The spectrum of
the 19 identiﬁed mutations, consisted in 14 missense muta-
tions and 5 null alleles. Two mutations were of uncertain
consequences without mRNA analysis, the c.735G>T on
the last nucleotide of exon 3 that could lead either to
p.Glu245Asp or to an aberrant splicing, and the
c.735 + 3:A>Gwhich abolish the splice donor site of exon 3.
3.3. Baseline cardiac and skeletal muscular status (Tables 2,
3a and 3b)
Baseline cardiac and muscle assessments were completed
in all patients.
Muscle involvementwas identiﬁed at baseline evaluations
in 21/28 patients, including 19 probands in whom muscle
biopsy revealedmyoﬁbrillar myopathy, 1 relative with a pre-
viously undiagnosed myopathy, and 1 relative with mild
asymptomatic weakness on physical examination.
Cardiac involvement was present in 27/28 patients, includ-
ing isolated or combined conduction abnormalities in 25,
supraventricular arrhythmias in 4, ventricular arrhythmias in
2, and myocardial disease in 14. Thirteen patients complained
of symptoms suggestive of underlying heart or respiratory dis-
ease such as dyspnea, syncope, palpitations or lightheadedness.
Nine patients had suﬀered from P1 major cardiac AEs
1–17 years prior to baseline evaluation. Among the 9 relatives
of probands carrying aDESmutation, previously undiagnosed
cardiac diseasewas identiﬁed in 6, including 4whohadnomus-
cle involvement. In addition, from family history, we identiﬁed
16 additional ﬁrst- or second-degree relatives among 9 families
who had histories of complete AV block, sustained ventricular
tachyarrhythmia, or sudden death (no. 2, 4, 10–11, 13–15, 17,
19) and could not undergo genetic testing. Advanced conduc-
tion system disease requiring permanent pacing was present
in 14 relatives, of whom 6 died suddenly.
3.4. Long-term clinical outcomes (Fig. 2, additional
material)
The average follow-up, complete in all but 2 (no. 4–1
and 13–2) of the 28 patients, was 10.4 ± 9.4 years. Patient
Table 2
Baseline characteristics of the 28 patients included in this analysis.
Age, y 37.7 ± 14.4
Women 11 (39.2)
Muscular assessment
Muscle weakness 21 (75.0)
Functional status: wheelchair bound/ambulatory 3 (10.7)/18 (57.1)
Muscle weakness topography:
 Proximal/distal/both
 Lower limbs/upper limbs/both
 Axial
 Facial
1 (3.0)/7
(25.0)/12 (35.7)
1 (3.0)/2
(7.0)/18 (57.1)
18 (64.2)
6 (21.4)
Previous history of major cardiac adverse events
3d degree AV block 7 (25.0)
Sustained ventricular tachycardia 1 (3.5)
Hospitalization for heart failure 2 (7.0)
Cardiac symptoms
Lightheadedness 5 (18.5)
Palpitations 9 (33.3)
Dyspnea 9 (32.1)
Electrocardiogram
Normal 3 (10.7)
1st degree AV block, bundle branch block, or
fascicular block
10 (35.7)
Bifascicular block/trifascicular block 5 (17.8)/4 (14.2)
Paced rhythm 6 (21.4)
Echocardiography
Normal 12 (42.8)
Dilated/hypertrophic/restrictive cardiomyopathy 3 (10.7)/8 (28.5)/1
(3.5)
Left ventricular systolic dysfunction 5 (17.8)
Right ventricular disease 6 (21.4)
24-h ambulatory electrocardiogram
Supraventricular arrhythmias 4 (14.8)
Ventricular arrhythmias 1 (3.7)
Sinus pauses 1 (3.7)
Treatment
Pacemaker 10 (35.7)
Implantable cardioverter deﬁbrillator 1 (3.5)
Angiotensin-converting enzyme inhibitor 7 (25.0)
Beta-adrenergic blocker 8 (29.6)
Loop diuretic 4 (14.8)
Oral anticoagulant 4 (14.8)
Table 3a
Individual baseline characteristics.
Family–
patient
Sex Age Muscle
involvement
CK** DES
mutations
1–1* M 54 Y 4 p.Leu338Arg
2–1* F 33 Y NL p.Pro419Ser
2–2 M 50 Y 1.3 p.Pro419Ser
2–3 F 71 N NL p.Pro419Ser
3–1* F 33 Y NL c.640–2A>C
3–2 F 27 N NL c.640–2A>C
4–1* M 38 Y 4 p.Asp336Tyr
5–1* M 36 Y NL p.X471Tyr
6–1* F 44 Y 5 p.Lys144X
6–2 M 74 N NL p.Lys144X
7–1* M 25 Y 4.5 p.Arg454Trp
8–1* F 33 Y 1.1 p.Glu245Asp
8–2 F 9 N NL p.Glu245Asp
9–1* F 31 Y 1.05 p.Arg406Trp
10–1* M 54 Y 1.5 p.Glu439Lys
10–2 M 28 N NL p.Glu439Lys
11–1* M 49 Y 1.8 p.Ser2Ile
12–1* M 44 Y 2.9 p.Ser2Ile
13–1* F 44 Y NL p.Thr442Ile
13–2 F 27 N 1.4 p.Thr442Ile
13–3 M 36 Y 3.1 p.Thr442Ile
14–1* M 48 Y 2.7 p.Asn342Asp
15–1* M 29 N NL c.735 + 3A>G
16–1* M 29 Y 5 p.Arg355Pro
17–1* M 27 Y 1.3 p.Arg454Trp
18–1* F 30 Y NL p.Glu413Arg
18–2 M 16 Y NL p.Glu413Arg
19–1* M 33 Y 2.9 p.Leu345Pro
* Probands.
** CK value indicates X-fold the upper normal limit of measurement for
individual clinical laboratories.
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4–1 was lost to follow-up after year 2007, and patient 13–2
was alive at the end of the study, according to the National
Death Index.
Five patients died at a mean age of 58.0 ± 6.5 years,
representing a 17.8% mortality rate, including 3 for whom
cardiac complications were the primary cause of death
(age = 60.3 ± 5.5): Patient 13–1 died suddenly 18 years
after the implantation of a pacemaker, which could not
be interrogated post mortem; Patients 10–1 and 13–3 died
of end stage heart failure due to dilated cardiomyopathy
with a contraindication to cardiac transplantation because
of severe respiratory insuﬃciency. In addition, 2 patients
died due to iatrogenic complications of cardiac treatment:
Patient 7–1 who received immunosuppressive drugs after
cardiac transplantation died from lymphoma with pulmon-
ary infection; Patient 11–1 died of hemorrhagic stroke on
oral anticoagulants for atrial ﬁbrillation.
Major cardiac AEs developed in 13/28 patients, including
high degree conduction defects requiring permanent pacing
in 8, sustained ventricular tachycardia in 1, hospitalizations
Table 3b
Individual baseline cardiac investigations.
Fam–
Pt
History of cardiac disease (age) Cardiac symptoms ECG 24-h ambulatory
ECG
Echocardiography Treatment
Cardiomyopathy LVEF RV
disease
1–1* – – Bifascicular
block
– – 0.68 N –
2–1* – Palpitations Bifascicular
block
– – 0.65 N –
2–2 – Lightheadedness,
palpitations
Bifascicular
block
– Dilated 0.45 N Pacemaker
2–3 – Lightheadedness,
palpitations
Trifascicular
block
– Hypertrophic 0.63 N Pacemaker
3–1* 3rd degree AVB (32) – Paced
rhythm
– – 0.62 N Pacemaker
3–2 3rd degree AVB (26) – Paced
rhythm
– – 0.70 N Pacemaker
4–1* 3rd degree AVB (37) Dyspnea Trifascicular
block
– Dilated 0.45 N Pacemaker
5–1* 3rd degree AVB (35) – Paced
rhythm
– – 0.65 N Pacemaker
6–1* NSVT (37) Dyspnea LBBB NSVT Dilated 0.4 N –
6–2 – – – Hypertrophic 0.65 Y –
7–1* Hospitalization for HF (19) Dyspnea – – Hypertrophic 0.20 Y –
8–1* 3rd degree AVB (23) – Paced
rhythm
– Hypertrophic 0.68 Y Pacemaker
8–2 – Palpitations RBBB Atrial ﬂutter – 0.65 N –
9–1* 3rd degree AVB (14) – Paced
rhythm
Atrial ﬁbrillation – 0.65 N Pacemaker
10–1* Atrial ﬁbrillation (51) – Trifascicular
block
– – 0.65 Y –
10–2 – – RBBB – – 0.69 N –
11–1* – Palpitations Bifascicular
block
– Hypertrophic 0.70 N –
12–1* – – LPFB – Hypertrophic 0.69 N –
13–1* – – LBBB – – 0.68 N –
13–2 – – – – – 0.65 N –
13–3 – Palpitations RBBB – – 0.57 N –
14–1* – Lightheadedness 1st degree AVB Sinuspauses – 0.62 N Pacemaker
15–1* Lightheadedness,
palpitations
Trifascicular
block
– Hypertrophic 0.70 N Pacemaker
16–1* – – Bifascicular
block
– – 0.65 Y –
17–1* Atrial ﬁbrillation, SVT,
3rd degree AVB,
Hospitalization for HF (24)
Dyspnea, syncope Atrial
ﬁbrillation,
paced rhythm
– Restrictive 0.30 Y ICD
18–1* – Lightheadedness,
palpitations
LAFB – – 0.65 N –
18–2 – – LBBB – Hypertrophic 0.65 N –
19–1* – – RBBB – – ND N –
* Probands.
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for heart failure in 7, and cardioembolic stroke in 1. Seven
out of the thirteen patients had no cardiac symptom at
baseline.
Among the 19 patients with conduction blocks on the
ECG at baseline and no prior history of major conduction
defects, 8 developed high degree conduction disease, after a
mean follow-up of 6 years, whereas no patient with normal
ECG developed such complication. High degree blocks
became apparent as syncope or decompensation of heart
failure and required the implantation of a pacemaker in
emergency. Pacemakers were replaced by implantable
cardioverter deﬁbrillators in 3 patients who developed
sustained ventricular tachyarrhythmias, or who had family
history of sudden death despite the implantation of a
pacemaker.
Heart failure decompensation requiring treatment as
inpatients occurred in 7 patients, 3 of whom underwent
cardiac transplantation and 2 died. Among these 7 patients
with severe heart failure, the cardiomyopathy patterns dis-
played by echocardiography were restrictive in 1, hypertro-
phic in 1, and dilated in 5. Echocardiography at baseline
was normal in 4 out of these 7 patients.
Three out of the 9 probands’ relatives carrying DES
mutation developed major cardiac AEs, including 1 patient
who died due to heart failure.
3.5. Occurrence of muscle and cardiac involvement over
lifetime
The mean age at onset of disease was 31.7 ± 13.3 years.
The ﬁrst manifestations of the disease were muscle weakness
in 11 patients who all developed cardiac involvement after
6.3 ± 3.5 years and cardiac involvement in 16 patients, 10
of whom developed muscle disease after 6.8 ± 4.1 years.
Among the patients with a cardiac onset, 6 presented with
major cardiac complications, including a 14-year old patient
who underwent a pacemaker implantation for syncope due
to 3rd degreeAVblock. Another patient presented at 8 years
with atrial ﬂutter revealed by palpitations.
3.6. Correlations between clinical presentation and genetic
characteristics
No correlations were found between cardiac involve-
ment, and muscle phenotype or genetic characteristics,
including location of the mutation in the protein (head,
1B and 2B helix domains, or tail) and type of mutation
(nonsense, missense or splice).
4. Discussion
The main observations made in our study were (1) a
high cardiac mortality and morbidity in DES mutations
carriers, and (2) the absence of correlations between geno-
type and phenotype or skeletal and cardiac muscle involve-
ment. The strengths of our study are (1) the number of
patients included, (2) the standardized protocol of investi-
gations, and (3) the mean 10-year duration of follow-up.
We found in this population suﬀering from desminopa-
thy cardiac involvement in 27 and muscle involvement in
21/28 of patients. Life-threatening cardiac complications
were observed in 13 patients, at a mean age of 40 years,
including sudden death, endstage heart failure, AV block
and syncope requiring permanent pacing, and sustained
ventricular tachycardia. These complications were the ﬁrst
manifestation of cardiac involvement in 1/3 of patients and
were also observed among relatives carrying DES mutation
without muscle involvement, including asymptomatic
patients. In addition, genetic analyses, muscle studies, or
type of cardiomyopathy did not predict the development
of advanced cardiac disease. Therefore, the severity and
unpredictability of cardiac complications suggest that car-
diac investigations should be systematically and regularly
repeated in all DES mutation carriers with a view to diag-
nose cardiac involvement as early as possible, including
those without muscle involvement. Mutations in other
genes than DES, such as LMNA, might be present and
responsible for the muscular and cardiac abnormalities in
some of our patients but we have no data that may hardly
support this hypothesis.The youngest patient in whom
major cardiac AEs were identiﬁed was 14 years of age, sug-
gesting the need to begin meticulous ECG and echocardio-
graphic surveillance no later than in adolescence.
The 18 diﬀerent variants that we found were spanning
all along the gene and consequently the protein. The muta-
tion spectrum seems to show that the null mutations were
preferentially located on the N-terminal domain of the pro-
tein (Domain 1A and 1B helix domain) putatively leading
to an absence of the mutant allele except the mutation
abolishing the termination codon. Only 1 missense muta-
tion (p.Ser2Ile) was located in the head domain. All other
substitutions acting as a dominant negative eﬀect were
located in the 2B helix and tail domains of the protein (7
in the 2B helix, and 5 in the tail domain). This extensive
location of mutations does not facilitate the correlations
studies between the genotype and the phenotype and no
particular correlation between mutation types or locations
Fig. 2. Cumulative incidence of major cardiac adverse events in the 28
patients included.
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and skeletal muscle or cardiac disease could emerge from
this work.
Conduction system disease was the most frequent
manifestation of the disease. Conduction abnormalities
were overall present in 25/28, and severe symptomatic
abnormalities of impulse propagation requiring permanent
pacing in nearly 16/28 of patients. Among patients present-
ing at baseline with 1st degree AV block, fascicular block, or
both, around 40% developed a higher degree of blocking,
after mean follow-up of 6.0 years. This suggests that the
implantation of a pacemaker should be systematically dis-
cussed with patients whose ECG reveals the presence of con-
duction abnormalities even in the absence of any symptom.
Ventricular arrhythmias as a common manifestation of
cardiac involvement have not been reported so far in DES
mutated patients but a single case report has already been
published underlying this occurrence [16]. Ventricular
arrhythmiaswere observed in 4 out of our patients, including
2 who developed hemodynamically unstable, and sustained
ventricular tachycardia. In addition, sudden death occurred
in 1 another patient and in 4 ﬁrst-degree relatives who
received permanent pacemakers for severe conduction
defects.However, in those cases, the devices’memories could
not be interrogated to conﬁrm ventricular arrhythmias. No
signiﬁcant association could be drawn between ventricular
arrhythmias, myocardial disease, and ventricular function,
suggesting that ventricular arrhythmias are implicated in
the sudden death of DES mutated patients regardless of
ventricular function. In these cases, it appears that cardio-
verter deﬁbrillator is a more usefulness tool in primary pre-
vention than pacemaker but this could not be statistically
proven.
The other prominent cause of morbidity and mortality
in our patients was myocardial disease, as 8 out of our
28 patients were hospitalized for treatment of heart failure,
and 5 developed end stage heart failure. Severe right ven-
tricular, and left ventricular myocardial involvement have
been observed, such a severe phenotype having also
reported earlier in 1 member of a large family [15]. Our ser-
ies of patients also document dilated, hypertrophic and
restrictive cardiomyopathies as the worsening factors in
heart failure, but statistical analyses did not identify any
correlation between type of cardiomyopathy and need for
hospitalization. Cardiac transplantation was performed in
3 of those patients, who had mild muscle weakness and
no respiratory insuﬃciency. Absence of complications spe-
ciﬁcally related to the genetic disease during follow-up, as
previously reported [17], conﬁrmed that cardiac transplan-
tation is a valuable therapeutic option in patients who have
developed end stage heart failure due to desminopathy.
4.1. Study limitations
Despite being the largest series of patients presenting
with desminopathy reported so far, the number of patients
may have been insuﬃcient to reach suﬃcient statistical
power to identify genotype- phenotype correlations.
5. Conclusions
Patients carrying DES mutations presenting with myo-
ﬁbrillar myopathies or without muscle involvement, are at
high risk of developing major cardiac complications, includ-
ing high-degree AV block, ventricular tachycardia and end
stage heart failure. In these patients cardiac investigations
are suggested to be performed, at the time of early diagnosis
and at a yearly basis during follow-up. Patient’s relative who
could potentially carryDESmutation should also be oﬀered
to the same work-ups even if muscle involvement is absent.
The prophylactic implantation of a pacemaker or a deﬁbril-
lator should systematically be discussed in patients present-
ing with conduction system disease.
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